Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation
ConditionGlaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKazakh Eye Research Institute
About this trial
This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.
Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Decision to treat by MP-CPC Laser
Patients diagnosed with Glaucoma
Patients aged 18 years old and above
Glaucoma that is inadequately controlled on medical therapy
Disqualifiers
Patients age less than 18 years
Patients unable or unwilling to provide informed consent to participate in the study
Patients potentially unavailable for follow up visits
Patients with significant scleral thinning
Trial design
Design model
Parallel
Treatments tested in this trial
MicroPulse transscleral cyclophotocoagulation
Procedure/SurgeryMicroPulse transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. Laser treatment will be applied transsclerally over the ciliary body using a power of 2500 mW. The treatment duration will be 100-120 seconds per hemifield, with 5-6 sweeps per hemifield.
Conventional transscleral cyclophotocoagulation
Procedure/SurgeryConventional transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. Laser treatment will be applied transsclerally over the ciliary body using a power of 1.4-2.3 W, with an exposure duration of 1.4-1.8 seconds per coagulation spot.
Treatment groups
20 Participants
are divided into 2 treatment groupsGroup A: MicroPulse transscleral cyclophotocoagulation groupExperimental treatment 1 intervention
Group B: Conventional transscleral cyclophotocoagulation groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Changes in intraocular pressure measurements between baseline and postoperative follow-up visits
Baseline (pre-operative condition) and post operative intraocular pressure will be measured
Time frame
Day 1, Day 3, Week 1, Week 2, Month 1Secondary outcomes
1
Rate of post surgical complications
Rate of post surgical complications such as Hypotony, Corneal Edema, Hyphema, Iritis, Vitreous Hemorrhage and Cystoid Macular Edema
Time frame
Day 1, Day 3, Week 1, Week 2, Months 1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov